PFG Private Wealth Management LLC Purchases 4,654 Shares of Danaher Corporation $DHR

Key Points

• PFG Private Wealth Management acquired 4,654 Danaher shares worth approximately $1.03 million, while institutional investors collectively own 79.05% of the company.
• Danaher is pursuing AI-driven growth through a collaboration with NVIDIA and plans to launch its first commercial-scale autonomous laboratory in early 2027.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $235.41; the company also recently beat quarterly earnings and revenue estimates.

PFG Private Wealth Management LLC acquired a new position in Danaher Corporation (NYSE:DHR - Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 4,654 shares of the conglomerate's stock, valued at approximately $1,031,000. Danaher makes up 0.4% of PFG Private Wealth Management LLC's holdings, making the stock its 20th largest holding.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. EP Wealth Advisors LLC bought a new position in shares of Danaher during the second quarter valued at about $3,807,000. Puzo Michael J purchased a new position in shares of Danaher in the second quarter worth about $8,624,000. Madison Asset Management LLC bought a new stake in shares of Danaher in the 2nd quarter valued at about $85,451,000. First Nebraska Trust Co bought a new stake in shares of Danaher in the 2nd quarter valued at about $14,106,000. Finally, Colton Groome Financial Advisors LLC purchased a new stake in Danaher during the 3rd quarter valued at about $592,000. Hedge funds and other institutional investors own 79.05% of the company's stock.

Trending Headlines about Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on DHR. The Goldman Sachs Group increased their target price on Danaher from $210.00 to $250.00 and gave the company a "buy" rating in a report on Monday, September 21st. Wall Street Zen raised Danaher from a "hold" rating to a "buy" rating in a research note on Saturday, October 10th. Weiss Ratings upgraded Danaher from a "hold (c-)" rating to a "hold (c)" rating in a research report on Wednesday, September 16th. Guggenheim boosted their price objective on Danaher from $200.00 to $250.00 and gave the company a "buy" rating in a research report on Thursday, October 1st. Finally, TD Cowen increased their price objective on Danaher from $236.00 to $255.00 and gave the company a "buy" rating in a research note on Tuesday. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $235.41.

Danaher Trading Up 3.0%

NYSE:DHR opened at $231.52 on Friday. The firm has a market capitalization of $162.76 billion, a P/E ratio of 41.12, a PEG ratio of 2.82 and a beta of 0.76. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The company's 50-day simple moving average is $213.55 and its 200 day simple moving average is $195.74.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating analysts' consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same quarter last year, the firm earned $0.77 earnings per share. The business's revenue for the quarter was up 5.5% on a year-over-year basis. As a group, analysts forecast that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. Danaher's dividend payout ratio is presently 28.42%.

Danaher Company Profile

Danaher Corporation NYSE: DHR is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.